Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum on October 30

Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum on October 30

<0> Cytori Therapeutics, Inc.Megan McCormick, +1-858-875-5279 </0>

(NASDAQ: CYTX) will give a company presentation at the Investor and Partnering Forum on Tuesday, October 30.

The following are specific details regarding Cytori’s presentation at the conference:

The presentation will be recorded and will be available on the Webcasts page of the Cytori’s the week following the conference.

The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industry’s most exciting technologies.

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.